Latest News
A new oral pill for geographic atrophy is being tested in an early-stage clinical trial.
In this issue:
- President's Corner
- Parallels Found Between AMD Changes and Liver Cells
- How a High-Fat Diet Influences AMD
- And more!
In this issue:
- Researchers Discover Mechanisms Underlying Drusen Formation
- President's Corner
- Targeting Drusen Production in the Retina
- FDA Approves New Treatment for Macular Degeneration
- And more!
BrightFocus Foundation, a premier private funder of vision research, today announced a request for proposals for projects supported through its Macular Degeneration Research program.
Free Educational Program Will Offer Expert Insight On Age-Related Macular Degeneration Condition
New evidence shows the same molecular pathway contributes to inflammation in AMD and lupus, helping to drive a hyperactive immune response in both diseases. The discovery could fast-track development and approval of existing anti inflammatory drugs to treat AMD.
The FDA has approved a new treatment for “wet” AMD. Known as Vabysmo™, it can extend time between treatments for up to four months.
Early research suggests that modifying cross-talk between the eye’s immune and vascular systems may be a new way to treat AMD.
As retinal cells transition from one state to another, they exhibit molecular changes that correspond to those of liver cells.
